The overview of modern approaches in treatment of triple negative breast cancer
Исследования и практика в медицине, 2020 By far the most aggressive subtype of breast cancer is triple negative cancer. The purpose of this review is to analyze current ideas about the pathogenesis, clinical characteristics of different subtypes of triple negative breast cancer, the nature of ...
A. A. Kharitonova +2 more
doaj +1 more source
Uptake Assays to Monitor Anthracyclines Entry into Mammalian Cells
Bio-Protocol, 2017 Anthracyclines, such as doxorubicin and daunorubicin, are DNA damaging agents that autofluoresce and can be readily detected in cells. Herein, we developed suitable assays to quantify and localize daunorubicin in mammalian cells.
Nicolas Brosseau +2 more
doaj +1 more source
Frontiers in Surgery, 2022 ObjectiveDetermine the predictive value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) combined with echocardiography in the diagnosis of anthracyclines-induced chronic cardiotoxicity.MethodsA total of 80 female breast cancer patients from ...
Yingjun Dong, Qiong Wu, Changqing Hu
doaj +1 more source
First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]
, 2016 The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F. +3 more
core +2 more sources
Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor
Chinese Medical Journal, 2018 Background: Cardiotoxicity is one of the most serious chronic complications of anthracyclines therapy. Assessment of the left ventricular ejection fraction (LVEF) fails to detect subtle cardiac dysfunction of left ventricular (LV).
Hui-Min Hu +4 more
doaj +1 more source
Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]
, 2006 Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo +7 more
core +2 more sources
Updates in Anthracycline-Mediated Cardiotoxicity
Frontiers in Pharmacology, 2018 Cardiotoxicity is one of the main adverse effects of chemotheraphy, affecting the completion of cancer therapies and the short- and long-term quality of life.
Canan G. Nebigil, Laurent Désaubry
doaj +1 more source
eLife, 2021 Chemotherapy resistance is a critical barrier in cancer treatment. Metabolic adaptations have been shown to fuel therapy resistance; however, little is known regarding the generality of these changes and whether specific therapies elicit unique metabolic
Shawn McGuirk +14 more
doaj +1 more source
DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown [PDF]
, 2011 Damage-associated molecular patterns (DAMPs) or cell death associated molecular patterns (CDAMPs) are a subset of endogenous intracellular molecules that are normally hidden within living cells but become either passively released by primary and ...
Agostinis, Patrizia +3 more
core +1 more source
Clinical outcome and prognostic factors in renal medullary carcinoma: a pooled analysis from 18 years of medical literature [PDF]
, 2015 INTRODUCTION: We describe clinical features and prognostic factors of renal medullary carcinoma (RMC) by performing a pooled analysis of all reported cases since 1995.
CORTESI, Enrico +5 more
core +1 more source